{
    "info": {
        "nct_id": "NCT03122509",
        "official_title": "Phase II Study to Assess the Efficacy of Durvalumab (MEDI4736) and Tremelimumab Plus Radiotherapy or Ablation in Patients With Metastatic Colorectal Cancer",
        "inclusion_criteria": "* Be willing and able to provide written informed consent for the trial.\n* Histologically- or cytologically- confirmed CRC.\n* Metastatic CRC.\n* Subjects have received at least two standard chemotherapy regimens for which they would be considered eligible (at least one containing a 5-fluoropyrimidine), or systemic chemotherapy is not indicated in the setting of low volume metastatic disease.\n* At least one tumor for which palliative RT is considered appropriate standard therapy (cohort 1); or, at least one tumor for which palliative ablation is considered appropriate standard therapy (cohort 2).\n* At least one index lesion that will not undergo RT or ablation, and which is measurable based on RECIST 1.1.\n* Be ≥ 18 years of age on day of signing informed consent.\n* Consent for tumor biopsies (for patients enrolled in stage 1 only) and blood draws for research purposes (for all patients).\n* Consent for use of available archived tissue and tumor obtained during a standard procedure, for research purposes.\n* Have a performance status of 0 or 1 on the ECOG Performance Scale.\n* Female subjects must either be of non-reproductive potential (i.e., post-menopausal by history: ≥60 years old and no menses for ≥ 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test within 2 weeks prior to starting treatment.\n* Demonstrate adequate organ function as defined all screening labs should be performed within 4 weeks prior to treatment initiation.\n\n  * Hemoglobin ≥ 8.0 g/dL\n  * Absolute neutrophil count (ANC) ≥1,500 /mcL\n  * Platelets ≥100,000 / mcL\n  * Serum creatinine ≤1.5 X upper limit of normal (ULN) OR\n  * Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) OR\n  * Serum creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.\n  * Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN\n  * AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases.\n\naCreatinine clearance should be calculated per institutional standard.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.\n* Chemotherapy, monoclonal antibody, targeted small molecule therapy, within 4 weeks prior to dose #1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (excluding alopecia or toxicity not anticipated to interfere with planned treatment on study).\n* Known or suspected MSI-H CRC.\n* Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1, including anti-PD-1, anti-PD-L1, anti-CD137, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, except for endocrinopathies and asymptomatic amylase/lipase.\n* If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention per clinical discretion of the investigator prior to starting therapy.\n* Concurrent active malignancy that requires systemic treatment.\n* Known CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable without evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. The use of topical steroids is permitted.\n* Active autoimmune disease requiring systemic immune suppressive treatment within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.\n* Has active, non-infectious pneumonitis.\n* Active or prior documented inflammatory bowel disease.\n* History of allogeneic organ transplant.\n* Has an active infection requiring systemic therapy.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).\n* Has known active and untreated Hepatitis B (e.g., HBsAg reactive) or active Hepatitis C (e.g., HCV RNA [qualitative] is detected).\n* Has received a live vaccine within 30 days prior to the first dose of trial treatment.\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab with the exceptions of premedication and intranasal, topical and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10mg/day of prednisone, or an equivalent corticosteroid.\n* Hypersensitivity to durvalumab or tremelimumab, or any excipients on the formulation.\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.\n* Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.\n* QT interval corrected for heart rate (QTc) ≥ 470ms calculated from 1 electrocardiogram (ECG) using Fridericia's Correction.\n* History of primary immunodeficiency.\n* Known history of previous clinical diagnosis of tuberculosis.\n* Subjects with uncontrolled seizures.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Be willing and able to provide written informed consent for the trial.",
            "criterions": [
                {
                    "exact_snippets": "Be willing and able to provide written informed consent for the trial.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "provision",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically- or cytologically- confirmed CRC.",
            "criterions": [
                {
                    "exact_snippets": "Histologically- or cytologically- confirmed CRC",
                    "criterion": "colorectal cancer (CRC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation method",
                            "expected_value": [
                                "histologically confirmed",
                                "cytologically confirmed"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Metastatic CRC.",
            "criterions": [
                {
                    "exact_snippets": "Metastatic CRC",
                    "criterion": "colorectal cancer (CRC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Metastatic CRC",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects have received at least two standard chemotherapy regimens for which they would be considered eligible (at least one containing a 5-fluoropyrimidine), or systemic chemotherapy is not indicated in the setting of low volume metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "Subjects have received at least two standard chemotherapy regimens",
                    "criterion": "number of standard chemotherapy regimens received",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "regimens"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for which they would be considered eligible",
                    "criterion": "eligibility for standard chemotherapy regimens",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one containing a 5-fluoropyrimidine",
                    "criterion": "chemotherapy regimen containing 5-fluoropyrimidine",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic chemotherapy is not indicated in the setting of low volume metastatic disease",
                    "criterion": "indication for systemic chemotherapy in low volume metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one index lesion that will not undergo RT or ablation, and which is measurable based on RECIST 1.1.",
            "criterions": [
                {
                    "exact_snippets": "At least one index lesion",
                    "criterion": "index lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "that will not undergo RT or ablation",
                    "criterion": "index lesion treatment status",
                    "requirements": [
                        {
                            "requirement_type": "planned RT or ablation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "which is measurable based on RECIST 1.1",
                    "criterion": "index lesion measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability (RECIST 1.1)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a performance status of 0 or 1 on the ECOG Performance Scale.",
            "criterions": [
                {
                    "exact_snippets": "performance status of 0 or 1 on the ECOG Performance Scale",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Consent for tumor biopsies (for patients enrolled in stage 1 only) and blood draws for research purposes (for all patients).",
            "criterions": [
                {
                    "exact_snippets": "Consent for tumor biopsies (for patients enrolled in stage 1 only)",
                    "criterion": "consent for tumor biopsies",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "enrollment stage",
                            "expected_value": "stage 1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Consent for ... blood draws for research purposes (for all patients)",
                    "criterion": "consent for blood draws for research purposes",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "all patients"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 8.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 8.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects must either be of non-reproductive potential (i.e., post-menopausal by history: ≥60 years old and no menses for ≥ 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test within 2 weeks prior to starting treatment.",
            "criterions": [
                {
                    "exact_snippets": "Female subjects",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "must either be of non-reproductive potential",
                    "criterion": "reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "non-reproductive"
                        }
                    ]
                },
                {
                    "exact_snippets": "post-menopausal by history: ≥60 years old and no menses for ≥ 1 year without an alternative medical cause",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "post-menopausal"
                        }
                    ]
                },
                {
                    "exact_snippets": "post-menopausal by history: ≥60 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no menses for ≥ 1 year without an alternative medical cause",
                    "criterion": "amenorrhea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of hysterectomy",
                    "criterion": "hysterectomy history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of bilateral tubal ligation",
                    "criterion": "bilateral tubal ligation history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of bilateral oophorectomy",
                    "criterion": "bilateral oophorectomy history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative serum pregnancy test within 2 weeks prior to starting treatment",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 2 weeks prior to starting treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Demonstrate adequate organ function as defined all screening labs should be performed within 4 weeks prior to treatment initiation.",
            "criterions": [
                {
                    "exact_snippets": "Demonstrate adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "all screening labs should be performed within 4 weeks prior to treatment initiation",
                    "criterion": "screening laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to treatment initiation"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥100,000 / mcL",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥100,000 / mcL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/ mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) ≥1,500 /mcL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥1,500 /mcL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) OR",
            "criterions": [
                {
                    "exact_snippets": "Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl)",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "measurement type",
                            "expected_value": [
                                "measured creatinine clearance",
                                "calculated creatinine clearance",
                                "GFR"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine CL>40 mL/min by the Cockcroft-Gault formula ... or by 24-hour urine collection for determination of creatinine clearance.",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "Cockcroft-Gault formula",
                                "24-hour urine collection"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine ≤1.5 X upper limit of normal (ULN) OR",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤1.5 X upper limit of normal (ULN)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN",
            "criterions": [
                {
                    "exact_snippets": "Serum total bilirubin ≤ 1.5 X ULN",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "applicability_condition",
                            "expected_value": "subjects with total bilirubin levels > 1.5 ULN"
                        }
                    ]
                }
            ]
        },
        {
            "line": "aCreatinine clearance should be calculated per institutional standard.",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance should be calculated per institutional standard.",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "per institutional standard"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases.",
            "criterions": [
                {
                    "exact_snippets": "AST (SGOT) ... ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases",
                    "criterion": "AST (SGOT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "X ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT (SGPT) ... ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases",
                    "criterion": "ALT (SGPT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "X ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST (SGOT) ... ≤ 5 X ULN for subjects with liver metastases",
                    "criterion": "AST (SGOT) level in subjects with liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "X ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT (SGPT) ... ≤ 5 X ULN for subjects with liver metastases",
                    "criterion": "ALT (SGPT) level in subjects with liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "X ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Be ≥ 18 years of age on day of signing informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Be ≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Consent for use of available archived tissue and tumor obtained during a standard procedure, for research purposes.",
            "criterions": [
                {
                    "exact_snippets": "Consent for use of available archived tissue ... for research purposes.",
                    "criterion": "archived tissue",
                    "requirements": [
                        {
                            "requirement_type": "consent for use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Consent for use of ... tumor obtained during a standard procedure, for research purposes.",
                    "criterion": "tumor obtained during a standard procedure",
                    "requirements": [
                        {
                            "requirement_type": "consent for use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "obtained during standard procedure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",
            "criterions": [
                {
                    "exact_snippets": "Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",
                    "criterion": "psychiatric disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interference with cooperation with the requirements of the trial",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",
                    "criterion": "substance abuse disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "interference with cooperation with the requirements of the trial",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).",
            "criterions": [
                {
                    "exact_snippets": "Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)",
                    "criterion": "Human Immunodeficiency Virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of previous clinical diagnosis of tuberculosis.",
            "criterions": [
                {
                    "exact_snippets": "Known history of previous clinical diagnosis of tuberculosis.",
                    "criterion": "history of clinical diagnosis of tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1, including anti-PD-1, anti-PD-L1, anti-CD137, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, except for endocrinopathies and asymptomatic amylase/lipase.",
            "criterions": [
                {
                    "exact_snippets": "Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent",
                    "criterion": "immune-related adverse event (irAE) during prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to enrollment"
                        },
                        {
                            "requirement_type": "association_with_treatment",
                            "expected_value": "while receiving any previous immunotherapy agent"
                        }
                    ]
                },
                {
                    "exact_snippets": "any unresolved irAE >Grade 1",
                    "criterion": "unresolved immune-related adverse event (irAE)",
                    "requirements": [
                        {
                            "requirement_type": "resolution_status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including anti-PD-1, anti-PD-L1, anti-CD137, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways",
                    "criterion": "prior immunotherapy agent type",
                    "requirements": [
                        {
                            "requirement_type": "agent_type",
                            "expected_value": [
                                "anti-PD-1",
                                "anti-PD-L1",
                                "anti-CD137",
                                "anti-CTLA-4 antibody",
                                "any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "except for endocrinopathies and asymptomatic amylase/lipase",
                    "criterion": "exception for specific irAEs",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "endocrinopathies",
                                "asymptomatic amylase/lipase"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy, monoclonal antibody, targeted small molecule therapy, within 4 weeks prior to dose #1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (excluding alopecia or toxicity not anticipated to interfere with planned treatment on study).",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy, monoclonal antibody, targeted small molecule therapy, within 4 weeks prior to dose #1",
                    "criterion": "prior systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (excluding alopecia or toxicity not anticipated to interfere with planned treatment on study)",
                    "criterion": "recovery from adverse events due to prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "at baseline"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has active, non-infectious pneumonitis.",
            "criterions": [
                {
                    "exact_snippets": "Has active, non-infectious pneumonitis.",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "infectious_status",
                            "expected_value": "non-infectious"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or suspected MSI-H CRC.",
            "criterions": [
                {
                    "exact_snippets": "Known or suspected MSI-H CRC",
                    "criterion": "MSI-H colorectal cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_status",
                            "expected_value": [
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with uncontrolled seizures.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with uncontrolled seizures",
                    "criterion": "seizures",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hypersensitivity to durvalumab or tremelimumab, or any excipients on the formulation.",
            "criterions": [
                {
                    "exact_snippets": "Hypersensitivity to durvalumab",
                    "criterion": "hypersensitivity to durvalumab",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hypersensitivity to ... tremelimumab",
                    "criterion": "hypersensitivity to tremelimumab",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hypersensitivity to ... any excipients on the formulation",
                    "criterion": "hypersensitivity to any excipients in the formulation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allogeneic organ transplant.",
            "criterions": [
                {
                    "exact_snippets": "History of allogeneic organ transplant.",
                    "criterion": "allogeneic organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent active malignancy that requires systemic treatment.",
            "criterions": [
                {
                    "exact_snippets": "Concurrent active malignancy that requires systemic treatment.",
                    "criterion": "concurrent active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.",
            "criterions": [
                {
                    "exact_snippets": "Female patients who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.",
                    "criterion": "willingness to employ effective birth control",
                    "requirements": [
                        {
                            "requirement_type": "willingness to employ effective birth control",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of birth control use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "duration of birth control use (durvalumab monotherapy)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 90,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known active and untreated Hepatitis B (e.g., HBsAg reactive) or active Hepatitis C (e.g., HCV RNA [qualitative] is detected).",
            "criterions": [
                {
                    "exact_snippets": "Has known active and untreated Hepatitis B (e.g., HBsAg reactive)",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "active Hepatitis C (e.g., HCV RNA [qualitative] is detected)",
                    "criterion": "Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.",
            "criterions": [
                {
                    "exact_snippets": "Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.",
                    "criterion": "any condition interfering with study evaluation or interpretation",
                    "requirements": [
                        {
                            "requirement_type": "investigator opinion of interference",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active or prior documented inflammatory bowel disease.",
            "criterions": [
                {
                    "exact_snippets": "Active or prior documented inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of primary immunodeficiency.",
            "criterions": [
                {
                    "exact_snippets": "History of primary immunodeficiency",
                    "criterion": "primary immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention per clinical discretion of the investigator prior to starting therapy.",
            "criterions": [
                {
                    "exact_snippets": "received major surgery",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have recovered adequately from the toxicity and/or complications from the intervention",
                    "criterion": "recovery from surgery toxicity and/or complications",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": "adequate"
                        }
                    ]
                },
                {
                    "exact_snippets": "per clinical discretion of the investigator",
                    "criterion": "investigator clinical discretion",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab with the exceptions of premedication and intranasal, topical and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10mg/day of prednisone, or an equivalent corticosteroid.",
            "criterions": [
                {
                    "exact_snippets": "Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab",
                    "criterion": "immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "temporal_relation",
                            "expected_value": "before first dose of durvalumab or tremelimumab"
                        }
                    ]
                },
                {
                    "exact_snippets": "exceptions of premedication and intranasal, topical and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10mg/day of prednisone, or an equivalent corticosteroid",
                    "criterion": "corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "intranasal",
                                "topical",
                                "inhaled"
                            ]
                        },
                        {
                            "requirement_type": "systemic dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg/day prednisone equivalent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable without evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. The use of topical steroids is permitted.",
            "criterions": [
                {
                    "exact_snippets": "Known CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with previously treated brain metastases may participate provided they are stable",
                    "criterion": "previously treated brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": "previously treated"
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without evidence of new or enlarging brain metastases",
                    "criterion": "new or enlarging brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "are not using steroids for at least 7 days prior to trial treatment",
                    "criterion": "systemic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "The use of topical steroids is permitted",
                    "criterion": "topical steroid use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* QT interval corrected for heart rate (QTc) ≥ 470ms calculated from 1 electrocardiogram (ECG) using Fridericia's Correction.",
            "criterions": [
                {
                    "exact_snippets": "QT interval corrected for heart rate (QTc) ≥ 470ms ... calculated from 1 electrocardiogram (ECG) using Fridericia's Correction",
                    "criterion": "QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "correction_method",
                            "expected_value": "Fridericia's Correction"
                        },
                        {
                            "requirement_type": "measurement_source",
                            "expected_value": "1 electrocardiogram (ECG)"
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 470,
                                "unit": "ms"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received a live vaccine within 30 days prior to the first dose of trial treatment.",
            "criterions": [
                {
                    "exact_snippets": "Has received a live vaccine within 30 days prior to the first dose of trial treatment.",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to first dose of trial treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active infection requiring systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Has an active infection requiring systemic therapy",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease requiring systemic immune suppressive treatment within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease requiring systemic immune suppressive treatment within the past 2 years",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic immune suppressive treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded",
                    "criterion": "vitiligo, Grave's disease, or psoriasis",
                    "requirements": [
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* At least one tumor for which palliative RT is considered appropriate standard therapy (cohort 1); or, at least one tumor for which palliative ablation is considered appropriate standard therapy (cohort 2).",
            "criterions": [
                {
                    "exact_snippets": "at least one tumor for which palliative RT is considered appropriate standard therapy (cohort 1)",
                    "criterion": "tumor",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "tumor"
                            }
                        },
                        {
                            "requirement_type": "palliative RT appropriateness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one tumor for which palliative ablation is considered appropriate standard therapy (cohort 2)",
                    "criterion": "tumor",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "tumor"
                            }
                        },
                        {
                            "requirement_type": "palliative ablation appropriateness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.",
            "criterions": [
                {
                    "exact_snippets": "Is currently participating in ... a study of an investigational agent",
                    "criterion": "participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study of an investigational agent within 4 weeks of the first dose of treatment",
                    "criterion": "participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "prior participation within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before first dose of treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "using an investigational device within 4 weeks of the first dose of treatment",
                    "criterion": "use of an investigational device",
                    "requirements": [
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before first dose of treatment"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}